ductal carcinoma

[Breast Cancer Research and Treatment] The authors highlight the unique characteristics of invasive lobular carcinoma (ILC) and describe the need for dedicated ILC clinical trials.

[PLoS One] To study laminin N-terminus α31 (LaNt α31) function, an adenoviral system was used to induce expression in MCF-7 and MDA-MB-231 cells. 2D cell migration and invasion into collagen hydrogels were not significantly different between LaNt α31 overexpressing cells and control treated cells.

[Pathology] Atypia in breast pathology may be cytonuclear and/or architectural with different applications and implications. Investigators provide a comprehensive review of atypia in breast pathology with reference to inconsistencies, challenges and limitations.

[Breast Cancer Research and Treatment] Breast cancer is immunogenic and a variety of vaccines have been designed to boost immunity directed against the disease. Newer approaches are designing vaccines to prevent breast cancer by intercepting high-risk lesions such as ductal carcinoma in situ to limit the progression of these tumors to invasive cancer.

[Scientific Reports] Scientists performed immune profiling to compare immune-related gene expression between ductal carcinoma in situ and invasive carcinoma of the breast using nCounter PanCancer immune Profiling Panel and found that CXCL10 was the most significant gene that had the highest difference in expression between them.

[Scientific Reports] Scientists investigated LGR5 expression in normal, benign, and malignant lesions of the human breast using RNA in situ hybridization, and suggested that LGR5 marked facultative stem cells that were involved in post injury regeneration instead of homeostatic stem cells.